In a significant string of defeats for major health insurance carriers, federal courts are increasingly signaling that they are not the appropriate venue for relitigating outcomes from the No Surprises Act (NSA) Independent Dispute Resolution (IDR) process. As of late May 2026, four separate federal courts have dismissed insurer-led lawsuits aimed at overturning arbitration awards, marking a decisive shift in how the landmark healthcare legislation is being enforced and interpreted in the courtroom.
The latest ruling, issued on May 28, 2026, by Judge Robert W. Schroeder III of the Eastern District of Texas, underscores a growing judicial consensus: the administrative framework established by the federal government for resolving out-of-network billing disputes is designed to be final, effectively shielding arbitration outcomes from secondary review by the judiciary.
The Core Conflict: Arbitrating the Cost of Care
The No Surprises Act, which took effect in early 2022, was designed to protect patients from the financial shock of unexpected medical bills when they receive out-of-network care. By removing patients from the middle of billing disputes, the law mandated an IDR process—a "baseball-style" arbitration system—to settle payment disagreements between insurers and healthcare providers.
While the policy goal of protecting the consumer has been largely successful, the mechanical implementation has sparked a secondary, high-stakes war between the nation’s largest insurance conglomerates and a burgeoning industry of medical billing intermediaries.
At the center of this controversy is HaloMD, a company founded in 2022 that specializes in navigating the IDR process for medical providers. Since its inception, HaloMD has scaled rapidly, becoming the largest initiator of IDR disputes in the United States. According to government data, the firm’s aggressive approach has helped its clients secure high-value arbitration wins, often at rates significantly higher than historical in-network benchmarks.
Chronology of a Legal Siege
The friction between insurers and firms like HaloMD has manifested in a flurry of federal litigation. Insurers have consistently argued that these companies are "gaming" the system, flooding the IDR process with thousands of ineligible claims to extract inflated payments.
2022–2024: The Rise of the IDR Industry
Following the passage of the NSA, medical providers faced a steep learning curve regarding the arbitration process. Companies like HaloMD stepped in to fill this gap, offering to handle the complex administrative filings required for IDR. As the volume of disputes climbed, providers began winning a vast majority of the cases. Industry data suggests that providers have prevailed in approximately 88% of determinations, often securing payments three to four times higher than comparable in-network rates.
2025: Insurer Counter-Offensive
Stung by the mounting costs, major insurers began filing civil lawsuits, alleging that HaloMD and similar entities were violating the spirit—and the letter—of the law. Notable cases included:
- BCBS Texas: A subsidiary of Health Care Service Corporation, the insurer filed suit last summer, claiming that HaloMD and its founders, Alla and Scott LaRoque, were responsible for tens of millions of dollars in "improper awards" stemming from fraudulent or ineligible claims.
- Elevance & Aetna: Similar suits were filed in California and Florida, respectively, attempting to invalidate awards and recover funds.
Spring 2026: The Judicial Firewall
The last six weeks have seen a dramatic collapse of the insurers’ legal strategy. Courts in Pennsylvania (UnitedHealth), California (Elevance), Florida (Aetna), and now Texas (BCBS) have all rejected the attempts to bring these disputes into the courtroom. In each instance, judges have cited the statutory language of the NSA, which limits the scope of judicial oversight over the IDR process.
Supporting Data: The IDR Disparity
The statistical landscape of the No Surprises Act reveals why the litigation has become so intense. When the law was first debated, many stakeholders expected a balanced split in arbitration outcomes. Instead, the data tells a story of clear provider dominance:
- Win Rates: Providers currently enjoy an 88% success rate in IDR determinations.
- Payout Premiums: Winning claims are frequently settled at rates 300% to 400% higher than typical in-network contracted rates.
- Volume: The sheer density of disputes has overwhelmed the administrative capacity of the system. HaloMD, in particular, has emerged as the volume leader, processing more disputes than any of its competitors, a fact that has drawn the scrutiny of federal regulators and the ire of insurance legal departments.
The financial implications are massive. For insurance companies, the cumulative impact of these arbitration losses has resulted in billions of dollars in unexpected medical spending, which they argue ultimately drives up premiums for the average American worker. Conversely, providers argue that these awards are necessary to compensate for the cost of providing emergency services in a landscape where insurers have consistently narrowed their provider networks.
Official Responses and Corporate Stance
The legal defeats have forced insurers to reconsider their strategy, while providers and their representatives are celebrating what they view as a vindication of the legislative design.
Justin Carangelo, General Counsel and Chief Compliance Officer for HaloMD, issued a sharp critique of the insurers’ legal tactics following the Texas ruling. "The court got this case exactly right," Carangelo stated. "The NSA forecloses judicial review of IDR awards. Insurers engaged in similarly wasteful litigation should assess whether continuing to do so is an intelligent use of resources."
For their part, insurance companies maintain that their litigation is a necessary response to a system they view as compromised. They argue that if the IDR process is not subject to judicial review, there is no check on "bad actors" who might abuse the administrative process to prioritize profit over equitable billing.
Implications for the Future of Healthcare Policy
The recent string of court dismissals has profound implications for the future of the American healthcare industry.
1. The Finality of Arbitration
By consistently ruling that they lack the jurisdiction to relitigate IDR awards, federal judges are cementing the arbitration process as a "black box." This means that unless Congress moves to amend the No Surprises Act to provide for more robust judicial oversight, the arbitration outcomes will remain final and binding, regardless of whether the insurer believes the claim was ineligible.
2. Regulatory Pressure
With the courts effectively closing the door on litigation, the pressure shifts to the federal government—specifically the Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS). Regulators are now the only ones with the authority to police the IDR process. We may see a shift toward more stringent "front-end" screening of claims to ensure that only eligible disputes reach the arbitration stage.
3. Continued Legal Uncertainty
While four federal courts have sided against insurers, the legal war is not entirely over. Ongoing litigation in Georgia and Ohio suggests that some insurers are still testing different legal theories. However, the precedent being set in the Eastern District of Texas and other jurisdictions is making it increasingly difficult for these suits to gain traction.
4. The Impact on Consumers
For the average patient, the legal battle between insurers and providers remains largely behind the scenes. However, the cost of this dispute is rarely absorbed entirely by the corporations involved. As the legal fees for these massive suits mount and the arbitration payouts continue to favor providers, the macro-economic reality remains: the cost of medical care in the United States continues to climb, and the No Surprises Act, while successful at protecting the patient from the "surprise," has created a complex and costly ecosystem for those who fund the care.
Conclusion
The judicial trend of 2026 confirms that the No Surprises Act was built with a rigid, administrative-first architecture. By attempting to bypass the IDR process and force federal judges to act as the final arbiter of medical billing disputes, insurance companies have faced a unified wall of opposition. For now, the "arbitration-first" status quo remains, leaving the industry to navigate a high-cost environment where the only path to reform appears to be through the halls of Congress or the offices of federal regulators, rather than the courtroom.
